Announcing our joint venture with European partner, Consilium Strategic Communications: Learn More

Westicke Partners IPO Advisory
Strategic Investor Relations
Independent Capital Markets Advice

Mobile Navigation

Westwicke Blog

The Westwicke Blog is designed to deliver information and insights into the ever-changing world of investor relations and the capital markets, with a specific focus on the healthcare industry.

What Public Company CEOs, CFOs Need to Know About After-Hours Trading

Posted on January 4th, 2017. Posted by

What Public Company CEOs, CFOs Need to Know About After-Hours Trading

As much as CEOs and CFOs know that they should focus on the long-term performance of their stocks, it’s impossible not to at least notice and wonder about day-to-day, hour-to-hour fluctuations, especially when they seem arbitrary and divorced from fundamentals.

Trading before the market opens and after it closes can be particularly confusing. For instance, outside of the regular market session, spreads can widen dramatically (see chart).

Continue Reading

Tips for Building a Better Investor Relations Plan

Posted on December 20th, 2016. Posted by

Tips for Building a Better Investor Relations Plan

Failing to plan, the old saying goes, is planning to fail. This is certainly true when it comes to your investor relations strategy. Yet even though strategic planning is every bit as important to your IR success as it is for every other part of your business, we find that many companies fail to plan correctly, if they plan at all.

IR planning is about delivering the right story to a well-defined audience, and about refreshing your message in a way that will continue to resonate with investors. Every good annual plan starts with the same question: What do you want to be different at the end of the year? So it’s vital to articulate your goals before formulating a strategy.

Continue Reading

Our Most Well-Read Investor Relations Posts of 2016

Posted on December 14th, 2016. Posted by

Our Most Well-Read Investor Relations Posts of 2016

After several years of extraordinary performance, healthcare stocks endured a challenging year in 2016. The Nasdaq Health Care and Biotechnology Indices were down almost 14 percent and more than 18 percent, respectively, year to date, through Dec. 12.

Whether you’re a leader of a public healthcare company, or a private company with plans for an IPO, carefully planned and flawlessly executed investor relations strategies are more important than ever during periods of increased scrutiny from Wall Street.

Continue Reading

Seven Tips to Help Ensure Successful Biotech Earnings Calls

Posted on December 7th, 2016. Posted by

Seven Tips to Help Ensure Successful Biotech Earnings Calls

Good CEOs and CFOs know that they only get a limited number of interactions with their buy-side and sell-side analysts each year. Analysts are busy people, with perhaps dozens of listed companies under coverage or on their watch lists. An earnings call is thus one of the few times that companies can have the undivided attention of their covering analysts and interested buy-siders. Use that time wisely. Here are some pointers to consider before you host your next biotech earnings call.

Continue Reading

Life for a Life Sciences Investor Relations Officer: Double Duty

Posted on November 15th, 2016. Posted by

Life for a Life Sciences Investor Relations Officer: Double Duty

Investor relations professionals have a tough job – but the life sciences industry presents some unique challenges: a strict regulatory environment, the politics surrounding healthcare reform, long product development timelines, and large investments in research and development. Implementing an IR program against that backdrop is daunting.

Yet that’s not all. The job of an IR officer in a life sciences company is uniquely complex, multifaceted, and demanding.

Continue Reading

Why Private Companies Should Meet the Buy Side Early

Posted on November 9th, 2016. Posted by

Why Private Companies Should Meet the Buy Side Early

Some people are a little surprised to hear that a decent percentage of our clients at Westwicke are private, venture-backed healthcare companies. “Why,” they ask, “do private companies need investor relations?”

Having spent the majority of my professional career on the buy side at one of the first U.S.-based healthcare crossover firms, I typically respond by saying: “I often wonder why it takes private companies so long before they do reach out to the buy side!”

Continue Reading

How to Engage with Sell-Side Analysts: Tips from the Source

Posted on November 2nd, 2016. Posted by

How to Engage with Sell-Side Analysts: Tips from the Source

As part of our Investor Relations Luncheon Series, we recently hosted a select group of biotechnology executives for a discussion with David Nierengarten and Heather Behanna, biotech analysts with Wedbush. The theme of the lunch was “How Best to Engage with Research Analysts.”

Continue Reading

Investor Relations: Overcoming Setbacks and Delays

Posted on October 25th, 2016. Posted by

Investor Relations: Overcoming Setbacks and Delays

I’ve seen pretty much everything during my career on Wall Street regarding investor relations. But there’s one thing I’ve never seen, and neither has anyone I know – a company that hasn’t run into unforeseen challenges, delays, or just bad news. Even the best-run companies have hiccups from time to time, whether it’s a missed quarter, bad clinical results, unexpected costs, or something else.

Continue Reading

ATM Financing: 6 Considerations for Public Companies

Posted on October 19th, 2016. Posted by

ATM Financing: 6 Considerations for Public Companies

As an executive, you understand the importance of formulating a long term capital sourcing strategy that will provide you the cash necessary to support your company’s growth. You are constantly asked in investor meetings: “How much cash do you have on the balance sheet?” “How long will that last you?” So how do you prepare to ensure that your business remains well capitalized?

Continue Reading

How to Answer the Buy Side’s Trickiest Questions

Posted on October 12th, 2016. Posted by

How to Answer the Buy-Side’s Trickiest Questions

“The analysts are projecting your revenue for next year” — a year in which you have not provided guidance — “at $50 million. Are you comfortable with this projection?”

Most CEOs and CFOs of public companies have heard a question like that — a “trick” question for which it seems any answer you give can potentially cause you problems. If you say you’re not “comfortable” with that revenue number, for example, do you risk projecting weakness to the investor community? On the other hand, do you want to effectively provide guidance before you formally release it?

Continue Reading

Westwicke Enters Partnership with Consilium Strategic Communications

Announcing our exciting new partnership that extends the Westwicke Partners footprint internationally.

LEARN MORE

Our Locations